First Human Trial of Partial Reprogramming Stem Cells
SkimNews Take
Prior failures in anti-aging treatments highlight the inherent difficulty of targeting specific aging pathways without disrupting broader cellular functions, making the nuanced control of partial reprogramming a critical test for iPSC technology's therapeutic potential.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- GlaxoSmithKline bought Sirtris Pharmaceuticals for $720 million in 2008 and terminated its resveratrol program in 2013 after the drug failed to deliver anti‑aging benefits.
- Shinya Yamanaka and Kazutoshi Takahashi published the iPSC discovery in Cell in 2006, showing that four Yamanaka factors can revert adult skin cells to pluripotency.
- Partial reprogramming has entered its first human clinical trial, testing whether short‑term activation of Yamanaka factors can rejuvenate cells without the cancer risk of permanent gene expression.
Why it matters: Biotech investors and aging patients stand to gain billions from a successful partial‑reprogramming therapy, while GlaxoSmithKline’s $720 million loss on resveratrol underscores the high financial stakes of anti‑aging hype.
Ask SkimNews
